FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases
- PMID: 12208741
FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases
Abstract
FK228 is a histone deacetylase (HDAC) inhibitor, the molecular mechanism of inhibition of which has been unknown. Here we show that reduction of an intramolecular disulfide bond of FK228 greatly enhanced its inhibitory activity and that the disulfide bond was rapidly reduced in cells by cellular reducing activity involving glutathione. Computer modeling suggests that one of the sulfhydryl groups of the reduced form of FK228 (redFK) interacts with the active-site zinc, preventing the access of the substrate. HDAC1 and HDAC2 were more strongly inhibited by redFK than HDAC4 and HDAC6. redFK was less active than FK228 in inhibiting in vivo HDAC activity, due to rapid inactivation in medium and serum. Thus, FK228 serves as a stable prodrug to inhibit class I enzymes and is activated by reduction after uptake into the cells. The glutathione-mediated activation also implicates its clinical usefulness for counteracting glutathione-mediated drug resistance in chemotherapy.
Similar articles
-
The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor.J Med Chem. 2007 Nov 15;50(23):5720-6. doi: 10.1021/jm0703800. Epub 2007 Oct 24. J Med Chem. 2007. PMID: 17958342
-
FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.Cancer Chemother Pharmacol. 2006 Nov;58(5):711-5. doi: 10.1007/s00280-005-0182-5. Epub 2006 Jan 25. Cancer Chemother Pharmacol. 2006. PMID: 16435156 Review.
-
Cyclic tetrapeptides bearing a sulfhydryl group potently inhibit histone deacetylases.Org Lett. 2003 Dec 25;5(26):5079-82. doi: 10.1021/ol036098e. Org Lett. 2003. PMID: 14682769
-
Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1.J Pharmacol Exp Ther. 2005 Apr;313(1):268-76. doi: 10.1124/jpet.104.072033. Epub 2005 Jan 5. J Pharmacol Exp Ther. 2005. PMID: 15634944
-
Histone deacetylase inhibitors from microorganisms: the Astellas experience.Prog Drug Res. 2008;66:335, 337-59. doi: 10.1007/978-3-7643-8595-8_7. Prog Drug Res. 2008. PMID: 18416310 Review.
Cited by
-
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.J Clin Oncol. 2015 Aug 10;33(23):2492-9. doi: 10.1200/JCO.2014.59.2782. Epub 2015 Jun 22. J Clin Oncol. 2015. PMID: 26101246 Free PMC article. Clinical Trial.
-
Targeting Histone Modifications in Bone and Lung Metastatic Cancers.Curr Osteoporos Rep. 2021 Jun;19(3):230-246. doi: 10.1007/s11914-021-00670-2. Epub 2021 Mar 15. Curr Osteoporos Rep. 2021. PMID: 33721181 Free PMC article. Review.
-
Discovery and mechanism of natural products as modulators of histone acetylation.Curr Drug Targets. 2012 Jul;13(8):1029-47. doi: 10.2174/138945012802008973. Curr Drug Targets. 2012. PMID: 22594471 Free PMC article. Review.
-
HDACs and HDAC Inhibitors in Cancer Development and Therapy.Cold Spring Harb Perspect Med. 2016 Oct 3;6(10):a026831. doi: 10.1101/cshperspect.a026831. Cold Spring Harb Perspect Med. 2016. PMID: 27599530 Free PMC article. Review.
-
Targeting the acetylation signaling pathway in cancer therapy.Semin Cancer Biol. 2022 Oct;85:209-218. doi: 10.1016/j.semcancer.2021.03.001. Epub 2021 Mar 8. Semin Cancer Biol. 2022. PMID: 33705871 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous